Physician profile
Emily Blodget
NPI 1033379268
$7,016.55
in general payments reported to CMS, 2019-2025
10 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,640 · 2021: $46.97 · 2022: $430 · 2023: $4,371 · 2024: $215 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,995 · Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,994.76 |
| Food and Beverage | $904.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $4,132.08 | 2023-2025 | Xacduro, Xerava, Zevtera |
| Shionogi INC | $1,346.82 | 2019 | |
| Merck Sharp & Dohme LLC | $740.46 | 2019-2025 | Zerbaxa, Prevymis, Recarbrio |
| Viiv Healthcare Company | $174.95 | 2019-2022 | |
| Abiomed | $141.66 | 2022 | |
| Shire North American Group INC | $124.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.22 | 2023 | Livtencity |
| Comsort, INC | $100.00 | 2019 | |
| Gilead Sciences, INC. | $96.71 | 2022 | |
| Melinta Therapeutics, LLC | $36.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Blodget listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.